Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Head/Neck
Head/Neck
This phase II trial tests whether reduced dose radiation therapy after transoral robotic surgery works in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer. HPV positive oropharyngeal cancer has a better prognosis than oropharyngeal cancer not caused by HPV. A standard of care treatment for HPV positive oropharyngeal cancer is transoral robotic surgery followed by radiation therapy. However, this treatment is associated with many long-term side effects including difficulty swallowing. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving reduced dose radiation therapy after transoral robotic surgery may improve swallowing outcomes and quality of life compared to standard of care dose radiation therapy after transoral robotic surgery.
Head/Neck
II
Topf, Michael
NCT05387915
VICC-ITHAN23125
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101
alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
Not Available
I
Berlin, Jordan
NCT05753722
VICC-DTPHI23182
Sparing Bone Marrow in Patients with Stage IIB-IV Lung Cancer, VMAT Trial
Lung
Lung
This phase II trial tests whether designing radiation to avoid bone marrow in the spine (vertebral bone marrow) leads to less reduction of white blood cell counts (lymphopenia) in patients with lung cancer. This sparing technique could lead to better disease control and outcome.
Lung
N/A
Osmundson, Evan
NCT05248256
VICCRAD2189
Evaluation of SNDX-5613 in Participants With Colorectal Cancer and Other Solid Tumors
Phase I
Phase I
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor
activity of SNDX-5613 in participants with colorectal cancer (CRC) or other solid tumors who
have failed at least 1 prior line of therapy.
activity of SNDX-5613 in participants with colorectal cancer (CRC) or other solid tumors who
have failed at least 1 prior line of therapy.
Phase I
I/II
Ciombor, Kristen
NCT05731947
VICCPHI22111
Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer Prostate Cancer Risk Clinic (PCRC) Study
Prostate
Prostate
Prostate
N/A
Tosoian, Jeffrey
VICCURO22121
Centers for Disease Control and Prevention - Community Counts: Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting
Benign Hematologic
Benign Hematologic
Benign Hematologic
N/A
Chi, Michelle
NCBH2301-CDC-REGISTRY
Descriptive Study of Pain Syndrome in Survivors of Head and Neck Cancer
Head/Neck
Head/Neck
Head/Neck
N/A
Kohutek, Zachary
VICC-VDHAN23178
Virtual 3D Intraoperative Communication System for Orthopedic Oncology: A Feasibility Study
Head/Neck
Head/Neck
Head/Neck
N/A
Topf, Michael
VICC-VDHAN23197
Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL-MF)
Melanoma
Melanoma
Melanoma
N/A
Zwerner, Jeffrey
VICCDERM22117
Prospective Observational Trial of a Biodegradable Hyaluronic Acid Spacer in Prostate Cancer Radiotherapy
Prostate
Prostate
Prostate
N/A
Kirschner, Austin
VICC-VDURO23220
